ViaCyte to Present at ARM’s Third Annual Regen Med Investor Day
SAN DIEGO, March 17, 2015 — ViaCyte, Inc., a privately-held regenerative medicine company with the first stem cell-derived islet replacement therapy for the treatment of diabetes in clinical trials, today announced a presentation by Dr. Paul Laikind, President and CEO, at the third annual Regen Med Investor Day co-hosted by the Alliance for Regenerative Medicine (ARM) and top financial firm Piper Jaffray.
Details of the presentation are as follows:
Session: Company Presentations
Date/Time: Wednesday, March 25th at 10:35 a.m. EDT
Location: Main Bar Room, Metropolitan Club, New York, N.Y.
Dr. Laikind will review recent progress with the company’s VC-01™ product candidate for the treatment of type 1 diabetes, which recently entered the clinical phase of development. A Phase 1/2 trial called STEP ONE, or Safety, Tolerability, and Efficacy of VC-01 Combination Product in Type 1 Diabetes, was launched in September 2014, and the first implant was announced in October 2014. The study is ongoing, with evaluation of safety and efficacy expected next year.
For more information, please visit the event’s website at www.arminvestorday.com.
ViaCyte is a privately-held regenerative medicine company focused on developing a novel cell therapy for the treatment of diabetes. ViaCyte is conducting a Phase 1/2 clinical trial of the Company’s lead VC-01 product candidate in patients with type 1 diabetes who have minimal to no insulin-producing beta cell function. ViaCyte’s VC-01 combination product is based on the production of pancreatic progenitor cells derived from human pluripotent stem cells. These progenitor cells are implanted in a durable and retrievable encapsulation device. Once implanted and matured, these cells are designed to secrete insulin and other regulatory factors in response to blood glucose levels. The VC-01 product is being developed as a potential long-term diabetes treatment without immune suppression, and without risk of hypoglycemia or other diabetes-related complications.
ViaCyte is headquartered in San Diego, California with additional operations in Athens, Georgia. The Company is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF.
For more information please visit www.viacyte.com.
VC-01™ is a registered trademark of ViaCyte, Inc.